IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe
IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities. The preclinical drug candidates are currently undergoing preparatory steps to meet the regulatory requirements for obtaining permission to conduct clinical phase I studies. Securing the intellectual property rights is an important step in protecting the results of the company’s research and strengthens the projects’ position and commercial potential.Drug candidates IRL942 and IRL1009 stem from IRLAB’s P001 research program and are